We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

97 hedge funds and large institutions have $450M invested in Epizyme, Inc in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 29 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 29

2% less funds holding

Funds holding: 9997 (-2)

7% less capital invested

Capital invested by funds: $485M → $450M (-$34.3M)

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

87% less call options, than puts

Call options by funds: $128K | Put options by funds: $975K

Holders
97
Holders Change
-2
Holders Change %
-2.02%
% of All Funds
2.59%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.11%
New
9
Increased
31
Reduced
29
Closed
11
Calls
$128K
Puts
$975K
Net Calls
-$847K
Net Calls Change
-$823K
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$410K +$10K +1,100 +3%
ProShare Advisors
52
ProShare Advisors
Maryland
$398K -$64.2K -7,033 -15%
GCP
53
GSA Capital Partners
United Kingdom
$382K +$355K +38,860 New
CS
54
Credit Suisse
Switzerland
$374K -$150K -16,486 -30%
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$372K
WC
56
Woodstock Corp
Massachusetts
$372K +$93.7K +10,266 +37%
Dimensional Fund Advisors
57
Dimensional Fund Advisors
Texas
$339K +$315K +34,468 New
DekaBank Deutsche Girozentrale
58
DekaBank Deutsche Girozentrale
Germany
$314K
Citadel Advisors
59
Citadel Advisors
Florida
$289K +$268K +29,349 New
Manulife (Manufacturers Life Insurance)
60
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$287K +$4.66K +510 +2%
MLICM
61
Metropolitan Life Insurance Company (MetLife)
New York
$270K -$33.5K -3,674 -12%
T. Rowe Price Associates
62
T. Rowe Price Associates
Maryland
$265K +$68.5K +7,500 +39%
Goldman Sachs
63
Goldman Sachs
New York
$229K +$66.1K +7,241 +45%
AIG
64
American International Group
New York
$228K +$319 +35 +0.2%
Jacobs Levy Equity Management
65
Jacobs Levy Equity Management
New Jersey
$220K -$144K -15,800 -41%
VEA
66
Virtus ETF Advisers
New York
$214K
BA
67
BlackRock Advisors
Delaware
$209K +$21.6K +2,365 +13%
Macquarie Group
68
Macquarie Group
Australia
$197K -$183K -20,000 -50%
TC
69
TFS Capital
Pennsylvania
$191K -$1.1M -120,035 -86%
JMPWA
70
JP Morgan Private Wealth Advisors
California
$156K
State Board of Administration of Florida Retirement System
71
State Board of Administration of Florida Retirement System
Florida
$151K
SO
72
STRS Ohio
Ohio
$127K
Wells Fargo
73
Wells Fargo
California
$124K -$913 -100 -0.8%
CIM
74
CIM Investment Management
Pennsylvania
$113K +$3.92K +430 +4%
BG
75
BlackRock Group
United Kingdom
$102K +$3.39K +371 +4%

EPZM Hedge Fund Activity: Q3 2016 in Review

97 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2016, worth a combined $450M — down 7.1% from $485M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of EPZM and 9 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 31 added.

The largest buyer was VOYA Investment Management, adding an estimated $7.87M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $7.73M sold.

  • 97 institutional investors held Epizyme, Inc (EPZM) as of Q3 2016, down from 99 in Q2 2016.
  • Funds reported $450M of Epizyme, Inc stock for Q3 2016, down 7.1% quarter-over-quarter.
  • 9 funds opened new Epizyme, Inc positions in Q3 2016 and 11 closed out, a net change of -2 holders.
  • The largest Epizyme, Inc buyer in Q3 2016 was VOYA Investment Management, an estimated $7.87M added.
  • The largest Epizyme, Inc seller in Q3 2016 was EcoR1 Capital, an estimated $7.73M sold.

Based on aggregated 13F filings for Q3 2016.